Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Basal cell carcinoma, drawn from the whole corpus: 13 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Hedgehog-inhibitor tolerability leads most patients to stop within a year.
Nothing recorded yet.
Background: Immune-related adverse events (irAEs). Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Resistance via SMO mutations has no approved next-in-class agent.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Resistance atlas · Lines of therapy.
Huge volume: dermatology and Mohs capacity, and cost of treating millions of low-risk lesions.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 17 changes by month →When this page itself was last checked or edited.
Advanced basal cell carcinoma after hedgehog inhibitor
A milestone in how this cancer is treated.
Locally advanced BCC recurrent after surgery or radiation, or not candidates
Objective response at 200 mg: 43% in locally advanced and 15% in metastatic basal cell carcinoma (central review).
A milestone in how this cancer is treated.